Unichem Laboratories Ltd's Q4FY25 Quarter Results
- 23 May 2025
Result Summary
- Unichem Laboratories Ltd reported a 19.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 7.5%.
- Its expenses for the quarter were down by 9.6% QoQ and up 4.1% YoY.
- The net profit decreased 323.5% QoQ and increased 192.1% YoY.
- The earnings per share (EPS) of Unichem Laboratories Ltd declined at 18.4 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 437.85 | 546.71 | 407.21 | -19.9% | 7.5% |
Total Expenses | 438.10 | 484.86 | 420.82 | -9.6% | 4.1% |
Profit Before Tax | -125.87 | 61.85 | -47.16 | -303.5% | 166.9% |
Tax | 3.44 | 4.00 | -2.89 | -14.0% | -219.0% |
Profit After Tax | -129.31 | 57.85 | -44.27 | -323.5% | 192.1% |
Earnings Per Share | -18.40 | 8.20 | -6.30 | -324.4% | 192.1% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Unichem Laboratories Ltd is a prominent player in the pharmaceutical industry. The company primarily focuses on the development, manufacturing, and marketing of pharmaceutical formulations. Its portfolio spans across various therapeutic segments, including cardiovascular, anti-infectives, gastrointestinal, and central nervous system drugs, among others. The company is known for its emphasis on research and development, aiming to deliver high-quality and affordable medications. As of the latest updates available up to October 2023, there are no specific major developments provided in the data. Any significant recent changes in the company’s operations, product launches, or strategic partnerships are not disclosed in this dataset.
Revenue
In the fourth quarter of fiscal year 2025 (Q4FY25), Unichem Laboratories Ltd reported a total income of ₹437.85 crores. This represents a decrease of 19.9% when compared to the third quarter of fiscal year 2025 (Q3FY25), where the total income stood at ₹546.71 crores. However, when compared year-over-year (YoY) with the fourth quarter of fiscal year 2024 (Q4FY24), there is a 7.5% increase from ₹407.21 crores. This data indicates fluctuations in revenue, with a notable decrease in income on a quarter-over-quarter (QoQ) basis despite an increase on a YoY basis. The reasons for these changes in revenue within the period are not provided in the data.
Profitability
Unichem Laboratories Ltd experienced a significant shift in profitability during the fourth quarter of fiscal year 2025. The profit before tax (PBT) was reported as a loss of ₹125.87 crores, marking a drastic decrease from a profit of ₹61.85 crores in the previous quarter (Q3FY25). This change reflects a QoQ decrease of 303.5%. Compared to the same quarter in the previous year (Q4FY24), where the PBT was a loss of ₹47.16 crores, there is a YoY decrease of 166.9%. The profit after tax (PAT) also followed a similar trend, showing a loss of ₹129.31 crores in Q4FY25, compared to a profit of ₹57.85 crores in Q3FY25, indicating a QoQ decrease of 323.5%. Year-over-year, the PAT reflects a decrease of 192.1% from a loss of ₹44.27 crores in Q4FY24. These figures suggest significant volatility in the company's profitability over the periods.
Operating Metrics
The operating expenses for Unichem Laboratories Ltd were ₹438.10 crores in Q4FY25, a decrease of 9.6% from ₹484.86 crores in the previous quarter (Q3FY25). When compared to Q4FY24, which recorded expenses of ₹420.82 crores, there is a YoY increase of 4.1%. The earnings per share (EPS) for Q4FY25 were reported as a loss of ₹18.40, down from a profit of ₹8.20 in Q3FY25, marking a QoQ decrease of 324.4%. This also represents a YoY decrease of 192.1% from a loss of ₹6.30 in Q4FY24. The tax expense for Q4FY25 was ₹3.44 crores, slightly lower than the ₹4.00 crores in Q3FY25, reflecting a QoQ decrease of 14.0%. Year-over-year, this is an increase from a tax benefit of ₹2.89 crores in Q4FY24, marking a YoY change of -219.0%. This data highlights significant changes in the company's operating metrics over the specified periods.